Meanwhile, TET2 mutations may synergized with other gene mutations [e.g., DNA Methyltransferase 3A (DNMT3A), Isocitrate Dehydrogenase 2(IDH2), etc.] to affect the response of MDS patients to hypomethylating agents. Here, DNMT3A is linked to myelodysplastic syndrome.